A new open-science platform aims to spotlight reproducibility - BioCentury.com

"Having helped expose the reproducibility crisis about five years ago, Amgen Inc. is staying at the forefront of the issue with its support of F1000Research, an open-science platform to let researchers check each other's data. But as the field wrestles with causes and solutions, some academics are starting to bristle at the intrusion. The issue was sparked by a pair of papers in 2011 and 2012 from Bayer AG and Amgen, respectively, that showed each company could only reproduce a small percentage of published data when the experiments were tried in-house ..."